30 September 2021
The Government has announced that ofatumumab (Kesimpta®) will be listed under the Pharmaceutical Benefit Scheme (PBS) from Friday 1 October 2021. It is the first PBS-listed B-cell therapy that can be self-administered at home by Australian adults with relapsing remitting multiple sclerosis (RRMS).
This follows the March 2021 approval of ofatumumab (Kesimpta®) as a new medication for MS, by the Therapeutic Goods Association (TGA).